Categories Earnings, Health Care

Agilent Technologies (NYSE: A): Q1 2020 Earnings Snapshot

— Agilent Technologies, Inc. (NYSE: A) reported its first-quarter 2020 adjusted earnings of $0.81 per share, up 7% year-over-year. This came in line with the analysts’ expectations.

— Revenue grew by 5.7% to $1.36 billion versus $1.35 billion expected.

Agilent Technologies (A) Q1 2020 earnings snapshot

— Life Sciences and Applied Markets Group sales rose 5% on continued strength in Environmental & Forensics markets and stable Chemical & Energy.

— Agilent CrossLab Group grew by 6% on continued performance across both services and consumables.

— Diagnostics and Genomics Group saw 6% growth aided by continued strong Nucleic Acids Solutions Division, high single-digit growth in the Next-Generation Sequencing portfolio and mid-single-digit growth in Pathology related businesses.

— Looking ahead into the second quarter of 2020, the company expects revenue in the range of $1.28-1.32 billion and adjusted earnings of $0.72-0.76 per share. Analysts expect EPS of $0.79 on revenue of $1.34 billion.

— The estimated impact of Coronavirus in China of about $10 million revenue deferred into Q2, mostly in Life Sciences and Applied Markets Group.

— For the full year 2020, the company still predicts revenue in the range of $5.50-5.55 billion and adjusted earnings of $3.38-3.43 per share. The consensus estimates EPS of $3.42 on revenue of $5.54 billion.

We’re on Flipboard! Follow us to receive the latest stock market, earnings, and financial news at your fingertips

Most Popular

Earnings Preview: UnitedHealth looks poised to end FY24 on a positive note

UnitedHealth Group (NYSE: UNH), a leading provider of health insurance and healthcare services, is expected to report fourth-quarter earnings next week. The company, a market leader in the nation's colossal

Mattel (MAT): A look at the toymaker’s evolving strategy and its opportunities

Shares of Mattel, Inc. (NASDAQ: MAT) stayed green on Wednesday. The stock has dropped 4% over the past month. Over the past few years, the toymaker has been focused on

AngioDynamics (ANGO) reports net loss for Q2 2025; sales drop 8%

AngioDynamics Inc. (NASDAQ: ANGO) reported a net loss for the second quarter of 2025 as the medical device company’s revenues decreased 8%. Net loss, excluding special items, was $0.04 per

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close